Erbitux Companion Test Approval Clears Path For Further Co-Development
This article was originally published in The Gray Sheet
Executive Summary
DakoCytomation expects reimbursement policies for ImClone's Erbitux colorectal cancer drug to guide adoption of companion diagnostic EGFR pharmDx
You may also be interested in...
ViroLogic Gets Molecular Cancer Test Platform With Aclara
ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1
ViroLogic Gets Molecular Cancer Test Platform With Aclara
ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1
Ventana Developing Companion Diagnostic For Novartis’ Gleevec Cancer Drug
Ventana Medical Systems expects to submit a premarket approval application by early next year for a c-kit diagnostic for use with Novartis' drug Gleevec (imatinib mesylate)